Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update

Ultragenyx Pharma (RARE) PT Lowered to $66 at Citi

August 5, 2019 6:26 AM EDT

Citi analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $66.00 (from $69.00) while maintaining a Neutral rating.

... More

Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat

August 1, 2019 5:39 PM EDT

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.02 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $24.15 million versus the consensus estimate of $22.52 million.

The U.S. launch of Crysvita continues to be strong with the number of patients on reimbursed... More